Press Releases

Press Releases

Samsung Biologics Hits Growth in FY19 Profits, Sets Global Expansion Plan with Enhanced Service Lineup in 2020

Samsung Biologics Hits Growth in FY19 Profits, Sets Global Expansion Plan with Enhanced Service Lineup in 2020  


Samsung Biologics Co., Ltd. (CEO: Dr. Tae Han Kim) announced through its earnings release today that the company posted revenues of 701.6 billion Korean won, operating profit of 91.7 billion won, and net profit of 202.9 billion won for the 2019 fiscal year. 


Sales increased by 165.8 billion won (+30.9%) and operating profit increased by 36 billion won (+64.6%) compared to the previous year, due to increased operations at all three plants and an improved Won-Dollar exchange rate. 


Net income decreased by 21.2 billion won (-9.5%), attributable to the cash inflow of 389.2 billion won in 2018 for the Asset Purchase Agreement (APA) with Biogen. 


Excluding the said amount 389.2 billion won for APA from net income in 2018, 2019 net income increased by 368 billion won. 


※ Samsung Biologics Yearly Financial Result 2019                                              (Billion KRW) 

 

2019

2018

YoY

Sales

701.6

535.8

165.8 (+30.9%)

Operating Profit

91.7

55.7

36.0 (64.6%)

Net Income

202.9

224.1

-21.2 (-9.5%)

Debt

(Ratio)

1,557.2

(35.8%)

1,824.9

(43.9%)

-2677.7

(-8.1%)

 

Sales for the fourth quarter was 313.3 billion won, an increase of 128.5 billion won (+69.5%) from the third quarter due to a much improved operations rate from Plant 2 and sales recognition from Plant 3. Operating profit in the fourth quarter increased by 83.3 billion won (+353.0%) to 106.9 billion won from the third quarter, attributable to increased sales and significant structural changes in the product lineup. 


Meanwhile, Samsung Biologics announced at the recent J.P. Morgan Healthcare Conference that it has signed a total of 35 CMO, 42 CDO, and 10 CRO contracts to date and that the company is targeting to win an additional 12 CMO and 18 CDO contracts or more in 2020. 

 

During the conference, Samsung Biologics also announced plans to open its first CDO R&D lab abroad in San Francisco this year to widen its sales footprint and improve client proximity, and that it will target above 60% capacity utilization of Plant 3 by year end through vigorous sales activities. 

Samsung Biologics Hits Growth in FY19 Profits, Sets Global Expansion Plan with Enhanced Service Lineup in 2020 


Samsung Biologics Co., Ltd. (CEO: Dr. Tae Han Kim) announced through its earnings release today that the company posted revenues of 701.6 billion Korean won, operating profit of 91.7 billion won, and net profit of 202.9 billion won for the 2019 fiscal year. 


Sales increased by 165.8 billion won (+30.9%) and operating profit increased by 36 billion won (+64.6%) compared to the previous year, due to increased operations at all three plants and an improved Won-Dollar exchange rate. 


Net income decreased by 21.2 billion won (-9.5%), attributable to the cash inflow of 389.2 billion won in 2018 for the Asset Purchase Agreement (APA) with Biogen. 


Excluding the said amount 389.2 billion won for APA from net income in 2018, 2019 net income increased by 368 billion won. 


※ Samsung Biologics Yearly Financial Result 2019                                              (Billion KRW) 

 

2019

2018

YoY

Sales

701.6

535.8

165.8 (+30.9%)

Operating Profit

91.7

55.7

36.0 (64.6%)

Net Income

202.9

224.1

-21.2 (-9.5%)

Debt

(Ratio)

1,557.2

(35.8%)

1,824.9

(43.9%)

-2677.7

(-8.1%)

 

Sales for the fourth quarter was 313.3 billion won, an increase of 128.5 billion won (+69.5%) from the third quarter due to a much improved operations rate from Plant 2 and sales recognition from Plant 3. Operating profit in the fourth quarter increased by 83.3 billion won (+353.0%) to 106.9 billion won from the third quarter, attributable to increased sales and significant structural changes in the product lineup. 


Meanwhile, Samsung Biologics announced at the recent J.P. Morgan Healthcare Conference that it has signed a total of 35 CMO, 42 CDO, and 10 CRO contracts to date and that the company is targeting to win an additional 12 CMO and 18 CDO contracts or more in 2020. 

 

During the conference, Samsung Biologics also announced plans to open its first CDO R&D lab abroad in San Francisco this year to widen its sales footprint and improve client proximity, and that it will target above 60% capacity utilization of Plant 3 by year end through vigorous sales activities. 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION